UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 10-Q

                  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                For The Quarterly Period Ended December 31, 2008

                        Commission File Number: 000-52458


                           ARKSON NUTRACEUTICALS CORP.
             (Exact Name of Registrant as Specified in its Charter)

          DELAWARE                                               51-0383940
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                     4653 Carmel Mountain Road, Ste. 308-129
                           San Diego, California 92130
          (Address of principal executive offices, including zip code)

                                 (858) 525-3157
              (Registrant's telephone number, including area code)

                                   Copies to:
                             Daniel C. Masters, Esq.
                        P. O. Box 66, La Jolla, CA 92037
                                 (858) 459-1133

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the Registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company (as
defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer [ ]                        Non-accelerated filer [ ]
Accelerated filer [ ]                              Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [X] No [ ]

There were 545,889 shares of the Registrant's Common Stock outstanding as of
December 31, 2008.
<PAGE>
ITEM 1. FINANCIAL STATEMENTS.

The un-audited quarterly financial statements for the period ended December 31,
2008, prepared by the company, immediately follow.



                                       2
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                 As of              As of
                                                              December 30,         June 30,
                                                                 2008                2008
                                                               ---------           ---------
<S>                                                            <C>                 <C>
ASSETS

Current Assets
  Cash                                                         $      --           $      --
                                                               ---------           ---------
      Total Assets                                                    --                  --

LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)

Note to an officer & shareholder                                  11,606              11,606
Note to an unrelated party                                         1,000               1,000
                                                               ---------           ---------
      TOTAL LIABILITIES                                           12,606              12,606

Stockholders' Equity (Deficit)
  Common stock, $.0001 par value:
    200,000,000 shares authorized, 10,917,780 shares
    issued and outstanding as of 6/30/2008
    545,889 shares issued and outstanding as of 9/30/2008             55               1,092
  Additional paid in capital                                     123,725             122,688
  Retained Earnings                                                   --                  --
  Deficit accumulated during the development stage              (136,386)           (136,386)
                                                               ---------           ---------
      Total Shareholders' Equity (Deficit)                       (12,606)            (12,606)
                                                               ---------           ---------

      TOTAL LIABILITIES & STOCKHOLDERS' EQUITY                 $      --           $      --
                                                               =========           =========
</TABLE>


                        See Notes to Financial Statements

                                       3
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                             STATEMENT OF OPERATIONS

<TABLE>
<CAPTION>
                                                                                                     From Inception
                                                                                                     October 2, 1998
                                         Six Months Ended                   Years Ended                  through
                                            December 31,                      June 30,                 December 31,
                                      2008            2007             2008             2007              2008
                                   -----------     -----------      -----------      -----------       -----------
<S>                                <C>             <C>              <C>              <C>               <C>
Revenue                            $        --     $        --      $        --      $        --       $        --
                                   -----------     -----------      -----------      -----------       -----------
Total Revenue                               --              --               --               --                --

General & Admin Exps                        --              --               --            5,000           136,610
                                   -----------     -----------      -----------      -----------       -----------

Operating Income (Loss)                     --              --               --           (5,000)         (136,610)
                                   -----------     -----------      -----------      -----------       -----------
OTHER INCOME (EXPENSE)
  Interest Income                           --              --               --               --               290
  Other Income                              --              --               --               --               194
                                   -----------     -----------      -----------      -----------       -----------
                                            --              --               --               --               484
INCOME TAX
  Current income tax                        --              --               --               --              (260)
  Income tax benefit                        --              --               --               --                --
                                   -----------     -----------      -----------      -----------       -----------

NET INCOME (LOSS)                  $        --     $        --      $        --      $    (5,000)      $  (136,386)
                                   ===========     ===========      ===========      ===========       ===========

Basic and diluted earning
 (Loss) per Share                           --              --               --         (0.00045)
                                   -----------     -----------      -----------      -----------

Weighted average number
 of common shares
 outstanding                         2,687,910      10,917,780       10,917,780       10,917,780
</TABLE>


                        See Notes to Financial Statements

                                       4
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                  STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

<TABLE>
<CAPTION>
                                                                           Accumulated
                                      Common Stock           Additional       During         Total
                                  ---------------------       Paid in      Development    Stockholders
                                  Shares         Amount       Capital         Stage          Equity
                                  ------         ------       -------         -----          ------
<S>                             <C>             <C>          <C>            <C>            <C>
Balance, July 1, 2006           10,917,780      $ 1,092      $122,688      $(131,386)       $ (7,606)

Common stock issued
 for services                   39,000,000        3,900        (3,900)

Common stock cancelled         (39,000,000)      (3,900)        3,900

Net loss for year
 ended June 30, 2007                                                          (5,000)         (5,000)
                               -----------      -------      --------      ---------        --------
Balance, June 30, 2007          10,917,780        1,092       122,688       (136,386)        (12,606)

Common stock issued                     --
Net loss for year
 ended June 30, 2008                                                              --              --
                               -----------      -------      --------      ---------        --------
Balance, June 30, 2008          10,917,780        1,092       122,688       (136,386)        (12,606)

Common stock issued                     --
1 for 20 reverse split         (10,371,891)      (1,037)        1,037
Net loss for quarter
 Ended December 31, 2008                                                          --              --
                               -----------      -------      --------      ---------        --------

Balance, December 31, 2008         545,889      $    55      $123,725      $(136,386)       $(12,606)
                               ===========      =======      ========      =========        ========
</TABLE>


                        See Notes to Financial Statements

                                       5
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                             STATEMENT OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                                                         From Inception
                                                                                                         October 2, 1998
                                                   Six Months Ended                Years Ended               through
                                                      December 31,                   June 30,              December 31,
                                                 2008           2007            2008           2007           2008
                                              ----------     ----------      ----------     ----------     ----------
<S>                                           <C>            <C>             <C>            <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)                             $       --     $       --      $       --     $   (5,000)    $ (136,386)
                                              ----------     ----------      ----------     ----------     ----------
Adjustments to reconcile net income (loss)
 to net cash (used in) operations                     --             --              --             --             --
                                              ----------     ----------      ----------     ----------     ----------
NET CASH PROVIDED BY (USED IN) OPERATIONS             --             --              --         (5,000)      (136,386)
                                              ----------     ----------      ----------     ----------     ----------
CASH FLOWS FROM INVESTING ACTIVITIES

NET CASH PROVIDED BY INVESTING ACTIVITIES             --             --              --             --             --
                                              ----------     ----------      ----------     ----------     ----------
CASH FLOWS FROM FINANCING ACTIVITIES
  Loan from officer/shareholder                       --             --              --          5,000        (42,384)
  Loan from related party                             --             --              --             --         54,990
  Common stock issuance                               --             --              --             --        123,780
                                              ----------     ----------      ----------     ----------     ----------
NET CASH PROVIDED BY FINANCING ACTIVITIES             --             --              --             --        136,386
                                              ----------     ----------      ----------     ----------     ----------
NET INCREASE (DECREASE)                               --             --              --             --             --
                                              ----------     ----------      ----------     ----------     ----------
CASH BEGINNING OF PERIOD                              --             --              --             --             --
                                              ----------     ----------      ----------     ----------     ----------
CASH END OF PERIOD                            $       --     $       --      $       --     $       --     $       --
                                              ==========     ==========      ==========     ==========     ==========

SUPPLEMENTAL DISCLOSURES OF
CASH FLOW INFORMATION
  Interest paid                               $       --     $       --      $       --     $       --     $       --
                                              ----------     ----------      ----------     ----------     ----------
  Income taxes paid                           $       --     $       --      $       --     $       --     $      260
                                              ----------     ----------      ----------     ----------     ----------
</TABLE>


                        See Notes to Financial Statements

                                       6
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                          Notes to Financial Statements
              December 31, 2008 and 2007 and June 30, 2008 and 2007


NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

THE COMPANY

Arkson Nutraceuticals Corp. (the "Company"), was incorporated in the state of
Delaware on October 2, 1998. The Company was organized to manufacture and sell a
broad range of natural health food supplements. The Company currently has no
operations and, in accordance with Statement of Financial Accounting Standard
(SFAS) No. 7, "ACCOUNTING AND REPORTING BY DEVELOPMENT STAGE ENTERPRISES," is
considered a development stage enterprise.

Its activities to date have been limited to capital formation, organization,
development of its business plan, and discussions with representatives of
private label manufacturers and wholesale buyers of natural supplements.

CASH AND CASH EQUIVALENTS

For purposes of the statements of cash flows, the Company considers cash
instruments with original maturities of less than three months to be cash
equivalents.

START-UP COSTS

Costs of start-up activities, including organization costs, are expensed as
incurred, in accordance with Statement of Position (SOP) 98-5.

INCOME TAXES

The Company accounts for income taxes under SFAS No. 109, "Accounting for Income
Taxes." This statement requires an asset and liability approach to account for
income taxes. The Company provides deferred income taxes for temporary
differences that will result in taxable or deductible amounts in future years
based on the reporting of certain costs in different periods for financial and
income tax purposes. There is no income tax for the periods ended December 31,
2008 or 2007 or June 30, 2008 or 2007. The Company has net operating loss carry
forward from prior years that may be used to reduce future taxable income for
income tax purposes.

USE OF ESTIMATES

The presentation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the financial statements, and the reported
amounts of revenues and expenses during the periods presented. Actual results
may differ significantly from those estimates.

FAIR VALUES OF FINANCIAL INSTRUMENTS

Statement of Financial Accounting Standards No. 107, DISCLOSURES ABOUT FAIR
VALUE OF FINANCIAL INSTRUMENTS, requires disclosure of fair value information
about financial instruments, whether or not recognized in the balance sheet. In
cases where quoted market prices are not available, fair values are based on
estimates using present value or other valuation techniques. Those techniques
are significantly affected by the assumptions used, including the discount rate
and estimates of future cash flows.

                                       7
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                          Notes to Financial Statements
              December 31, 2008 and 2007 and June 30, 2008 and 2007


In that regard, the derived fair value estimates cannot be substantiated by
comparison to independent markets and, in many cases, could not be realized in
immediate settlement of the instruments. Statement No. 107 excludes certain
financial instruments and all non-financial instruments from its disclosure
requirements.

STOCK-BASED COMPENSATION

In accordance with the provisions of SFAS 123, the Company follows the intrinsic
value based method of accounting as prescribed by APB 25, ACCOUNTING FOR STOCK
ISSUED TO EMPLOYEES, for its stock-based compensation.

IMPACT OF NEW ACCOUNTING STANDARDS

The Company does not expect the adoption of recently issued accounting
pronouncements to have a significant impact on the Company's results of
operations, financial position, or cash flow. As new accounting pronouncements
are issued, the Company will adopt those that are applicable under the
circumstances.

NOTE 2 - STOCKHOLDERS' EQUITY

COMMON STOCK

Effective August 7, 2008 the Company amended its Articles of Incorporation
increasing its authorized share capital. As a result, the Company now has
authorized two hundred million (200,000,000) shares of common stock, having one
hundredth of a cent ($0.0001) par value per share, and fifty million
(50,000,000) shares of preferred stock, also having one hundredth of a cent
($0.0001) par value per share.

On October 2, 1998 the Company issued a total of 9,250,000 shares to its three
founders for services rendered in connection with the organization of the
Company. Also in 1998 the Company issued 600,000 shares of common stock for
cash, net of offering costs, in the amount of $6,000. Also in 1998 the Company
issued 1,000,000 shares of common stock for cash, net of offering costs, in the
amount of $50,000. In 1999 the Company issued 16,000 shares of common stock for
cash, net of offering costs, in the amount of $16,000.

In 2000 the Company issued 50,000 shares of common stock for cash, net of
offering costs, in the amount of $50,000, and also issued 1,780 shares for
services valued at $1,780.

In the first quarter of 2007 the Company voted to issue 39,000,000 shares of
common stock to its president in exchange for services, however this issuance
was cancelled before it took effect.

Effective August 7, 2008 the Company reverse split its issued and outstanding
common stock on the basis of one new share for each twenty old shares. Thus, as
of December 31, 2008 there were 545,889 shares of common stock issued and
outstanding and no preferred stock was outstanding.

NOTE 3 - EARNINGS PER SHARE

There were no earnings and losses for the quarters ended December 31, 2008 and
2007. There was a loss of $5,000 during the year ended June 30, 2007. Therefore
earnings (losses) per share for each of the quarters reported herein was $0.00,
and losses for the years ended June 30, 2008 and 2007 were $0.00 and
approximately $(0.00045) per share, respectively.

                                       8
<PAGE>
                           ARKSON NUTRACEUTICALS CORP.
                          (A Development Stage Company)
                          Notes to Financial Statements
              December 31, 2008 and 2007 and June 30, 2008 and 2007


For the quarters ended December 31, 2008 and 2007 and the years ended June 30,
2008 and 2007, and for the period October 2, 1998 (inception) to December 31,
2008 there were no shares issuable under stock options, warrants, or rights.
Therefore, diluted earnings per share were the same as basic earnings per share
at all times.

NOTE 4 - INCOME TAXES

At June 30, 2007, the Company has a net operating loss carry forward for tax
purposes of approximately $136,386 which expires through the year 2018. The
Internal Revenue Code contains provisions which may limit the loss carry forward
available if significant changes in stockholder ownership of the Company occur.

There were no provisions for income taxes for the years ended June 30, 2008 and
2007 or for the quarters ended December 31, 2008 and 2007.

NOTE 5 - RELATED PARTY TRANSACTIONS

LOANS PAYABLE

Between October 2, 1998 (Inception) and December 31, 2003 certain officers and
shareholders made a number of non-interest bearing loans to the Company totaling
$54,990 and received principal repayments of those loans totaling $44,800. As of
December 31, 2003, 2004, and 2005 one shareholder was owed the principal sum of
$10,190. On February 6, 2006 that shareholder was repaid $2,585 of the sum owing
to him. In May that shareholder loaned an additional $4,000 to the Company and
another party loaned $1,000 to the Company. As a result, there was a liability
of $12,606 owed to two note holders as of December 31, 2008. These notes are
convertible into common stock at the rate of one share of common stock per
$0.001 of loan principal. Thus they are convertible into a total of 12,606,000
shares of common stock.

NOTE 6 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company's financial position and
operating results raise substantial doubt about the Company's ability to
continue. The Company has had no operating revenue since inception and is
currently not operating.

The ability of the Company to continue as a going concern is dependent upon
developing sales and obtaining additional capital and financing. The financial
statements do not include any adjustments that might be necessary if the Company
is unable to continue as a going concern.

NOTE 7- SUBSEQUENT EVENT

There is no subsequent event to disclose since the end of the second quarter on
December 31, 2008.

NOTE 8 - COMMITMENT AND CONTIGENTCY

There is no commitment or contingency to disclose during the years ended June
30, 2008 and 2007 or the quarters ended December 31, 2008 and 2007.

                                       9
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

FORWARD-LOOKING STATEMENTS.

     The discussion contained herein contains "forward-looking statements" that
involve risk and uncertainties. These statements may be identified by the use of
terminology such as "believes," "expects," "may," "should" or anticipates" or
expressing this terminology negatively or similar expressions or by discussions
of strategy. The cautionary statements made in this Form 10QSB should be read as
being applicable to all related forward-looking statements wherever they appear
in this Form 10QSB. Our actual results could differ materially from those
discussed in this report.

COMPANY HISTORY AND PLAN OF OPERATION.

     Arkson Nutraceuticals, Corp. (the "Company") was incorporated on October 2,
1998 under the laws of the State of Delaware. The Company intended to engage in
the manufacture and sale of a broad range of proprietary natural health food
supplement products. The Company began to negotiate licenses with developers of
natural health food supplements approximately one month after incorporation. The
Company also entered negotiations with various wholesale buyers of such products
and with finance organizations. These explorations and negotiations continued at
a high level for a period of approximately two years after incorporation, and at
a slower pace for one additional year. However, no such licenses or contracts
materialized.

     As a result of the Company's failure to generate sales it operated at a
loss. By June 30, 2001 all funds raised by the sale of shares had been expended,
and the Company thereafter became dormant. From July 1, 2001 until the present,
it was inactive and could be deemed to be a so-called "shell" company, whose
only purpose at this time is to determine and implement a new business purpose.
As a "shell" company, our sole purpose at this time is to locate and consummate
a merger or acquisition with a private entity. We have not yet identified any
company or companies which we hope to merge with or acquire.

LIQUIDITY AND CAPITAL RESOURCES.

     The Company has no current operating history and does not have any revenues
or earnings from operations. As of December 31, 2008, the Company had no assets
and liabilities of $12,606 and it had an accumulated deficit of $136,386.
Moreover, the Company has had no revenues from inception through December 31,
2008. We will, in all likelihood, sustain operating expenses without
corresponding revenues, at least until the closing of a merger with or
acquisition of an operating business. We expect these continued operating losses
to be small since the Company has no operations or employees.

     We are dependent upon our officers to meet any de minimis costs that may
occur. Our two officers and directors have agreed to provide the necessary
funds, without interest, for the Company to comply with the Securities Exchange
Act of 1934, as amended, provided that they are officers and directors of the
Company when the obligation is incurred. All advances are interest-free.

RESULTS OF OPERATIONS.

     The Company is still in its development stage and has no revenues to date.
It did not incur any operating expenses during the six month periods ended
December 31, 2008 or 2007. Its only activities during these periods was the
search for a merger or acquisition partner conducted by its president. The
search was conducted through occasional meetings and phone calls which did not
involve any expense to the Company. Our net loss since inception through
December 31, 2008 was $136,386. Most of this loss was incurred in 1998, 1999,
and 2000. While the company has no cash to meet expenses, our two officers and
directors have agreed to provide the necessary funds, without interest, for the
Company to comply with the Securities Exchange Act of 1934, as amended, provided

                                       10
<PAGE>
that they are officers and directors of the Company when the obligation is
incurred. While they have agreed to advance the funds, the agreement is verbal
and is unenforceable as a matter of law.

GOING CONCERN.

     The accompanying financial statements are presented on a going concern
basis. The company's financial condition raises substantial doubt about the
Company's ability to continue as a going concern. The Company does not have
significant cash or other material assets and it is relying on advances from
stockholders, officers and directors to meet its limited operating expenses.

OFF-BALANCE SHEET ARRANGEMENTS

     We do not have any off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that is material to
investors.

ITEM 4. CONTROLS AND PROCEDURES.

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

     Our management team, under the supervision and with the participation of
our principal executive officer and our principal financial officer, evaluated
the effectiveness of the design and operation of our disclosure controls and
procedures as such term is defined under Rule 13a-15(e) promulgated under the
Exchange Act, as of the last day of the fiscal period covered by this report,
December 31, 2008. The term disclosure controls and procedures means our
controls and other procedures that are designed to ensure that information
required to be disclosed by us in the reports that we file or submit under the
Exchange Act is recorded, processed, summarized and reported, within the time
periods specified in the SEC's rules and forms. Disclosure controls and
procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by us in the reports that we
file or submit under the Exchange Act is accumulated and communicated to
management, including our principal executive and principal financial officer,
or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure. Based on this evaluation, our principal
executive officer and our principal financial officer concluded that, as of
December 31, 2008, our disclosure controls and procedures were effective at a
reasonable assurance level.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

     There have been no changes in our internal control over financial reporting
during the fiscal quarter ended December 31, 2008 that materially affected, or
are reasonably likely to materially affect, our internal control over financial
reporting.

                          PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

     None

ITEM 1A. RISK FACTORS

     There have been no material changes to the risks to our business from those
described in our Annual Report on Form 10-K for the year ended June 30, 2008
filed with the SEC on August 19, 2008.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

     None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

     None

                                       11
<PAGE>
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     None

ITEM 5. OTHER INFORMATION

     Effective August 7, 2008 the Company amended its Articles of Incorporation
to increase the number of authorized shares of common stock from 50,000,000 to
200,000,000 and also to authorize 50,000,000 shares of preferred stock.
Effective on the same date the Company ordered a reverse split of its
outstanding common stock on the basis of one new share for twenty old shares,
thus reducing the total number of issued and outstanding shares of common stock
from 10,917,780 shares to 545,889 shares.

ITEM 6. EXHIBITS

No.                                     Description
---                                     -----------
31.1     Certification of Chief Executive Officer required by Rule 13a-14(a) or
         Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted
         pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2     Certification of Chief Financial Officer required by Rule 13a-14(a) or
         Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted
         pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1     Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as
         adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2     Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as
         adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Date: February 10, 2009          ARKSON NUTRACEUTICALS, INC.


                                 By: /s/ Robert Auduon
                                    ---------------------------------
                                    Robert Auduon
                                    President and Director


                                 By: /s/ Agatha Auduon
                                    ---------------------------------
                                    Agatha Auduon
                                    Treasurer and Director

                                       12